Abvc biopharma submitted vitargus® phase ii study plan to australia hrec

Fremont, ca, june 16, 2022 (globe newswire) -- via newmediawire – abvc biopharma, inc. (nasdaq: abvc), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today announced the submission of its vitrargus phase ii study to the australian bellberry human research ethics committee (hrec). if received, hrec approval will lead to a clinical trial notification (ctn) submission to the australian therapeutic goods administration (tga) for review, which is the final regulatory step before study initiation.
ABVC Ratings Summary
ABVC Quant Ranking